Streptococcal meningitis is bacterial meningitis caused by invasive Streptococcus species. Pneumococci, neonatal group B Streptococcus, and zoonotic Streptococcus suis reach the bloodstream from respiratory, genital, or swine-associated exposure sites, cross the blood-brain or blood-CSF barrier, replicate in the cerebrospinal fluid, and trigger acute neutrophilic meningeal inflammation with fever, headache, nuchal rigidity, and potentially permanent auditory or neurologic sequelae.
Ask a research question about Streptococcal meningitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Streptococcal meningitis
creation_date: "2026-09-30T02:43:53Z"
description: >-
Streptococcal meningitis is bacterial meningitis caused by invasive
Streptococcus species. Pneumococci, neonatal group B Streptococcus, and
zoonotic Streptococcus suis reach the bloodstream from respiratory, genital,
or swine-associated exposure sites, cross the blood-brain or blood-CSF
barrier, replicate in the cerebrospinal fluid, and trigger acute
neutrophilic meningeal inflammation with fever, headache, nuchal rigidity,
and potentially permanent auditory or neurologic sequelae.
category: Infectious Disease
disease_term:
preferred_term: streptococcal meningitis
term:
id: MONDO:0001316
label: streptococcal meningitis
parents:
- Bacterial meningitis
synonyms:
- Streptococcus meningitis
- Streptococcal bacterial meningitis
- Group B streptococcal meningitis
- Streptococcus suis meningitis
notes: >-
This is the etiologic parent for meningitis caused by Streptococcus species.
Species-specific child entries, such as Pneumococcal Meningitis, should carry
the full strain-specific capsule, toxin, vaccine, and resistance details.
review_notes: >-
Deliberately lumped. Streptococcal meningitis keeps pneumococcal, neonatal
group B Streptococcus, and zoonotic S. suis meningitides together at this
parent MONDO term because the species differ by age band, reservoir, exposure
route, and sequelae but share the same bacterial-meningitis compartment and
each clinically important species can still be curated as a species-specific
child when its mechanism, vaccine, or resistance details warrant it.
has_subtypes:
- name: Pneumococcal
display_name: Pneumococcal meningitis (Streptococcus pneumoniae)
classification: etiologic_species
curated_in: Pneumococcal_Meningitis
description: >-
Meningitis caused by Streptococcus pneumoniae, the commonest cause across
age groups. Curated in full in `Pneumococcal_Meningitis.yaml`.
subtype_term:
preferred_term: pneumococcal meningitis
term:
id: MONDO:0006913
label: pneumococcal meningitis
- name: GBS
display_name: Group B streptococcal meningitis (Streptococcus agalactiae)
classification: etiologic_species
description: >-
Neonatal and early-infant meningitis caused by Streptococcus agalactiae
acquired perinatally from maternal genital or gastrointestinal carriage, and
prevented by maternal screening with intrapartum antibiotic prophylaxis.
- name: S. suis
display_name: Streptococcus suis meningitis
classification: etiologic_species
description: >-
Zoonotic meningitis caused by Streptococcus suis acquired from swine or raw
pork exposure, with a high rate of persistent sensorineural hearing and
vestibular loss.
infectious_agent:
- name: Streptococcus pneumoniae
infectious_agent_term:
preferred_term: Streptococcus pneumoniae
term:
id: NCBITaxon:1313
label: Streptococcus pneumoniae
description: >-
Streptococcus pneumoniae is the pneumococcus that causes the pneumococcal
form of streptococcal meningitis across age groups.
evidence:
- reference: PMID:33370401
reference_title: Role of astroglial Connexin 43 in pneumolysin cytotoxicity and during pneumococcal meningitis.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
quote_role: BACKGROUND
snippet: >-
Streptococcus pneumoniae or pneumococcus (PN) is a major causative agent
of bacterial meningitis with high mortality in young infants and elderly
people worldwide.
explanation: >-
Identifies S. pneumoniae as a major bacterial-meningitis pathogen in the
age groups at the extremes of life.
- name: Streptococcus agalactiae
infectious_agent_term:
preferred_term: Streptococcus agalactiae
term:
id: NCBITaxon:1311
label: Streptococcus agalactiae
description: >-
Streptococcus agalactiae, or group B Streptococcus, causes neonatal
streptococcal meningitis, with serotype III/ST-17 lineages enriched among
meningitis and late-onset invasive disease.
evidence:
- reference: PMID:32060499
reference_title: "Multistate, Population-Based Distributions of Candidate Vaccine Targets, Clonal Complexes, and Resistance Features of Invasive Group B Streptococci Within the United States, 2015-2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Group B Streptococcus (GBS) is a leading cause of neonatal sepsis and
meningitis and an important cause of invasive infections in pregnant and
nonpregnant adults.
explanation: >-
Establishes GBS as a leading neonatal cause of sepsis and meningitis.
- reference: PMID:30833941
reference_title: Molecular Characteristics and Antimicrobial Resistance of Group B Streptococcus Strains Causing Invasive Disease in Neonates and Adults.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
ST-17 strains were more likely to cause meningitis and late-onset disease
than other strains.
explanation: >-
Supports the specific association between ST-17 GBS lineages, neonatal
meningitis, and late-onset invasive disease.
- name: Streptococcus suis
infectious_agent_term:
preferred_term: Streptococcus suis
term:
id: NCBITaxon:1307
label: Streptococcus suis
description: >-
Streptococcus suis is a swine-associated zoonotic Streptococcus that causes
adult bacterial meningitis after occupational or foodborne pig exposure.
evidence:
- reference: PMID:21779197
reference_title: Streptococcus suis meningitis with bilateral sensorineural hearing loss.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Streptococcus suis infection is an emerging zoonosis in Asia. The most
common disease manifestation is meningitis, which is often associated with
hearing loss and cochleovestibular signs.
explanation: >-
Identifies S. suis as a zoonotic cause of meningitis with a
hearing-and-vestibular complication pattern.
agent_life_cycle:
description: >-
Pneumococci and group B Streptococcus circulate primarily in human mucosal
niches before invasive spread, whereas S. suis is maintained in swine and
reaches people through occupational or raw-pork exposures; humans are the
clinical host for meningitis in all three branches.
hosts:
- preferred_term: Homo sapiens
role: clinical host and human mucosal reservoir
term:
id: NCBITaxon:9606
label: Homo sapiens
- preferred_term: Sus scrofa
role: zoonotic S. suis source host
term:
id: NCBITaxon:9823
label: Sus scrofa
evidence:
- reference: PMID:21779197
reference_title: Streptococcus suis meningitis with bilateral sensorineural hearing loss.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
S. suis infection in humans mainly occurs among risk groups that have
frequent exposure to pigs or raw pork.
explanation: >-
Supports the swine-associated zoonotic branch of the Streptococcus
meningitis lifecycle.
- reference: PMID:32060499
reference_title: "Multistate, Population-Based Distributions of Candidate Vaccine Targets, Clonal Complexes, and Resistance Features of Invasive Group B Streptococci Within the United States, 2015-2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Group B Streptococcus (GBS) is a leading cause of neonatal sepsis and
meningitis and an important cause of invasive infections in pregnant and
nonpregnant adults.
explanation: >-
Supports the human maternal-neonatal branch of invasive group B
Streptococcus disease.
classifications:
harrisons_chapter:
- classification_value: INFECTIOUS_DISEASES
transmission:
- name: Respiratory or genital Streptococcus acquisition
description: >-
Pneumococci colonize the upper airway and group B Streptococcus colonizes
maternal genital or gastrointestinal mucosa; invasive disease begins when
these mucosal organisms escape local containment and enter blood.
evidence:
- reference: PMID:32060499
reference_title: "Multistate, Population-Based Distributions of Candidate Vaccine Targets, Clonal Complexes, and Resistance Features of Invasive Group B Streptococci Within the United States, 2015-2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Group B Streptococcus (GBS) is a leading cause of neonatal sepsis and
meningitis and an important cause of invasive infections in pregnant and
nonpregnant adults.
explanation: >-
Supports GBS as a maternal-neonatal and adult invasive Streptococcus
species that belongs in the mucosal acquisition branch.
- name: Swine or raw-pork Streptococcus suis exposure
description: >-
Humans acquire zoonotic S. suis after frequent exposure to pigs, pork
carcasses, swine products, or raw pork and pig blood.
evidence:
- reference: PMID:21779197
reference_title: Streptococcus suis meningitis with bilateral sensorineural hearing loss.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
S. suis infection in humans mainly occurs among risk groups that have
frequent exposure to pigs or raw pork.
explanation: >-
Establishes pig and raw-pork exposure as the route into the zoonotic S.
suis meningitis branch.
- reference: PMID:19275779
reference_title: Hearing and vestibular loss in Streptococcus suis infection from swine and traditional raw pork exposure in northern Thailand.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A past history of the consumption of raw pork and/or pig's blood was found
in 62.5 per cent of cases, whereas contact with swine products was found
in 25 per cent.
explanation: >-
A northern Thailand case series quantified raw-pork or swine-product
exposures among culture-proven S. suis infections.
clinical_burden:
burden_level: HIGH
rationale: >-
Streptococcal species are leading causes of a global meningitis burden with
high mortality, concentrated in young children.
evidence:
- reference: PMID:41911930
reference_title: "Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The four WHO-defined preventable meningitis pathogens of interest (S
pneumoniae, N meningitidis, Haemophilus influenzae, and Group B
streptococcus) contributed to 98 700 deaths (77 000-127 000) and 594 000
cases (514 000-686 000).
explanation: >-
Quantifies the mortality and incidence burden to which S. pneumoniae and
Group B streptococcus contribute (GBD 2023).
environmental:
- name: Immunocompromising host conditions
description: >-
Asplenia, alcoholism, HIV infection and other immunocompromising conditions
raise the risk of invasive pneumococcal disease, including meningitis, and
are the conditions for which pneumococcal immunization is recommended.
disease_effect: PREDISPOSES
evidence:
- reference: PMID:16163421
reference_title: "[Prevention of community-acquired pneumonia in adults]."
supports: SUPPORT
evidence_source: OTHER
quote_role: REVIEW_SYNTHESIS
snippet: >-
Immunization is recommended in adults over 65 years old, in patients
affected by chronic diseases (cardiopathies, COPD, nephropathies, diabetes
mellitus, hepatic cirrhosis, chronic breakage in brain-blood barrier,
functional or anatomical asplenia, alcoholism), in immunocompromised hosts,
including HIV infection, chemotherapy treatment and hematological
malignancies.
explanation: >-
Lists asplenia, alcoholism and HIV infection among the host conditions
recognized as risk factors for invasive pneumococcal disease and warranting
vaccination.
pathophysiology:
- name: Mucosal or zoonotic Streptococcus invasion
role: trigger
description: >-
Meningitis-capable pneumococcal, GBS, or S. suis lineages colonize a
respiratory, genital, or swine-exposed entry surface and breach epithelial
and innate-immune containment.
biological_scale: ORGANISM
evidence:
- reference: PMID:21779197
reference_title: Streptococcus suis meningitis with bilateral sensorineural hearing loss.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Here, we report a case of S. suis meningitis in a 67-yr-old pig carcass
handler, who presented with dizziness and sensorineural hearing loss
followed by headaches.
explanation: >-
Illustrates direct occupational exposure as an entry route into zoonotic
S. suis meningitis.
downstream:
- target: Streptococcal Bacteremia
causal_link_type: DIRECT
description: >-
Organisms that escape the mucosa enter the bloodstream and disseminate.
- name: Streptococcal Bacteremia
description: >-
Bloodstream Streptococcus survives host clearance and reaches neurovascular
barriers.
biological_scale: ORGANISM
evidence:
- reference: PMID:32060499
reference_title: "Multistate, Population-Based Distributions of Candidate Vaccine Targets, Clonal Complexes, and Resistance Features of Invasive Group B Streptococci Within the United States, 2015-2017."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
directness: INDIRECT
snippet: >-
Nearly all isolates possessed capsule genes, 1-2 of the 3 main pilus gene
clusters, and 1 of 4 homologous alpha/Rib family determinants.
explanation: >-
Capsules and pilus adhesins mark the invasive GBS isolates that must
survive in blood before meningeal seeding.
downstream:
- target: Meningeal Streptococcus Seeding
causal_link_type: DIRECT
description: >-
Circulating bacteria cross the blood-brain or blood-CSF barrier and reach
the cerebrospinal-fluid compartment.
- name: Meningeal Streptococcus Seeding
description: >-
Streptococci that enter cerebrospinal fluid replicate beside the meninges
after pneumolysin-, adhesin-, and host-barrier interactions let bloodborne
organisms traverse the neurovascular barrier.
biological_scale: TISSUE
locations:
- preferred_term: blood-brain barrier
term:
id: UBERON:0000120
label: blood brain barrier
- preferred_term: cerebrospinal fluid
term:
id: UBERON:0001359
label: cerebrospinal fluid
cell_types:
- preferred_term: astrocyte
term:
id: CL:0000127
label: astrocyte
evidence:
- reference: PMID:33370401
reference_title: Role of astroglial Connexin 43 in pneumolysin cytotoxicity and during pneumococcal meningitis.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
PN also induced nuclear shrinkage in astrocytes associated with the loss of
BBB integrity, bacterial translocation across endothelial vessels and
replication in the brain cortex.
explanation: >-
Demonstrates the pneumococcal transition from bloodstream infection across
the blood-brain barrier into the brain in vivo.
downstream:
- target: Streptococcal CSF Replication
causal_link_type: DIRECT
description: >-
Once streptococci cross the barrier, organisms replicate in the
cerebrospinal-fluid and subarachnoid compartments.
- target: Pneumolysin-aCx43 Astroglial Cytotoxicity
causal_link_type: DIRECT
description: >-
Pneumococcal pneumolysin engages astroglial connexin-43 during meningeal
invasion.
- name: Streptococcal CSF Replication
role: consequence
description: >-
Streptococci multiply in the cerebrospinal fluid and expose resident glial
and recruited myeloid cells to cell-wall products and pneumococcal toxins.
biological_scale: ORGANISM
locations:
- preferred_term: cerebrospinal fluid
term:
id: UBERON:0001359
label: cerebrospinal fluid
- preferred_term: subarachnoid space
term:
id: UBERON:0000315
label: subarachnoid space
evidence:
- reference: PMID:33370401
reference_title: Role of astroglial Connexin 43 in pneumolysin cytotoxicity and during pneumococcal meningitis.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Following intravenous PN challenge, mice deficient for aCx43 developed
milder symptoms and showed severely reduced bacterial counts in the brain.
explanation: >-
The reduced brain bacterial burden in aCx43-deficient mice connects
barrier traversal to intracranial pneumococcal infection.
downstream:
- target: TLR-MMP Neutrophilic Meningeal Inflammation
causal_link_type: DIRECT
description: >-
Streptococcal products stimulate innate receptors and inflammatory
proteases, recruiting neutrophils into the CSF.
- name: Pneumolysin-aCx43 Astroglial Cytotoxicity
description: >-
Pneumococcal pneumolysin acts through astroglial connexin-43 (aCx43) gap
junctions to injure astrocytes and promote blood-brain-barrier traversal and
intracerebral bacterial replication.
biological_scale: CELLULAR
cell_types:
- preferred_term: astrocyte
term:
id: CL:0000127
label: astrocyte
biological_processes:
- preferred_term: cytolysis
modifier: INCREASED
term:
id: GO:0019835
label: cytolysis
downstream:
- target: Streptococcal CNS Injury
causal_link_type: DIRECT
description: >-
Astroglial cytotoxicity contributes to the parenchymal and barrier injury
of streptococcal CNS disease.
evidence:
- reference: PMID:33370401
reference_title: Role of astroglial Connexin 43 in pneumolysin cytotoxicity and during pneumococcal meningitis.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Here, we show that the astroglial connexin 43 (aCx43), a major gap
junctional component expressed in astrocytes, plays a predominant role
during PN meningitis.
explanation: >-
Identifies astroglial connexin-43 as the mediator of pneumolysin cytotoxicity
during pneumococcal meningitis.
- name: TLR-MMP Neutrophilic Meningeal Inflammation
role: consequence
description: >-
Streptococcal cell-wall products and pneumolysin trigger Toll-like-receptor
and NF-kappaB cytokine signaling, TNF-alpha release, matrix
metalloproteinase activation, and neutrophilic CSF inflammation.
biological_scale: TISSUE
cell_types:
- preferred_term: neutrophil
term:
id: CL:0000775
label: neutrophil
biological_processes:
- preferred_term: innate immune response
term:
id: GO:0045087
label: innate immune response
modifier: INCREASED
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
modifier: INCREASED
evidence:
- reference: PMID:19012971
reference_title: Effects of Toll-like receptor 2 agonist Pam(3)CysSK(4) on inflammation and brain damage in experimental pneumococcal meningitis.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Pam(3)CysSK(4) induced pleocytosis, TNF-alpha and MMP-9 in CSF in
sham-infection but not during acute meningitis.
explanation: >-
Shows that TLR2 stimulation is sufficient to induce CSF leukocytosis, TNF,
and MMP-9 in an infant-rat pneumococcal meningitis system.
downstream:
- target: Streptococcal CNS Injury
causal_link_type: DIRECT
description: >-
Cytokines and MMP-mediated barrier injury drive edema, vasculitis,
cochlear injury, and neuronal damage.
- target: Fever
description: >-
The meningeal inflammatory cytokine response produces fever.
- target: Headache
description: >-
Meningeal inflammation produces headache.
- target: Nuchal rigidity
description: >-
Meningeal inflammation produces the neck stiffness of meningism.
- name: Streptococcal CNS Injury
role: consequence
description: >-
Meningeal inflammation disrupts the blood-brain barrier and extends into
cortex, hippocampus, and cerebral vasculature, producing cognitive
morbidity, infarcts, and death.
biological_scale: TISSUE
locations:
- preferred_term: hippocampal formation
term:
id: UBERON:0002421
label: hippocampal formation
- preferred_term: cerebral cortex
term:
id: UBERON:0000956
label: cerebral cortex
downstream:
- target: Streptococcal Cochlear Injury
causal_link_type: DIRECT
description: >-
Inflammatory injury extends to the inner ear, producing cochlear damage.
- target: Coma
causal_link_type: DIRECT
description: >-
Severe cortical and systemic injury depresses consciousness to coma.
evidence:
- reference: PMID:24419461
reference_title: Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Adjuvant treatments with inhibitors of MMP-2 or MMP-2/9 prevented BBB
breakdown in the hippocampus, and treatments with inhibitors of MMP-2,
MMP-9 or MMP-2/9 prevented BBB breakdown in the cortex.
explanation: >-
Links the MMP inflammatory branch to barrier breakdown in hippocampus and
cortex during experimental pneumococcal meningitis.
- name: Streptococcal Cochlear Injury
description: >-
Inflammatory injury to the inner ear produces the persistent sensorineural
hearing and vestibular loss characteristic of streptococcal (notably S.
suis) meningitis survivors.
biological_scale: TISSUE
locations:
- preferred_term: cochlea
term:
id: UBERON:0001844
label: cochlea
downstream:
- target: Sensorineural hearing impairment
causal_link_type: DIRECT
description: >-
Cochlear injury produces persistent sensorineural hearing loss.
evidence:
- reference: PMID:19275779
reference_title: Hearing and vestibular loss in Streptococcus suis infection from swine and traditional raw pork exposure in northern Thailand.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
After a mean follow up of 17 months, 73 per cent of the surviving
meningitis cases had persistent sensorineural hearing loss and 50 per cent
demonstrated vestibular impairment.
explanation: >-
Quantifies persistent auditory and vestibular injury among S. suis
meningitis survivors.
phenotypes:
- name: Fever
phenotype_term:
preferred_term: Fever
term:
id: HP:0001945
label: Fever
evidence:
- reference: PMID:15509818
reference_title: Clinical features and prognostic factors in adults with bacterial meningitis.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The classic triad of fever, neck stiffness, and a change in mental status
was present in only 44 percent of episodes; however, 95 percent had at
least two of the four symptoms of headache, fever, neck stiffness, and
altered mental status.
explanation: >-
Identifies fever as one of the cardinal acute features of adult
community-acquired bacterial meningitis.
- name: Coma
phenotype_term:
preferred_term: Coma
term:
id: HP:0001259
label: Coma
frequency: OCCASIONAL
evidence:
- reference: PMID:15509818
reference_title: Clinical features and prognostic factors in adults with bacterial meningitis.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
On admission, 14 percent of patients were comatose and 33 percent had
focal neurologic abnormalities.
explanation: >-
Reports coma in 14% of adults at presentation with community-acquired
bacterial meningitis.
- name: Nuchal rigidity
phenotype_term:
preferred_term: Nuchal rigidity
term:
id: HP:0031179
label: Nuchal rigidity
evidence:
- reference: PMID:15509818
reference_title: Clinical features and prognostic factors in adults with bacterial meningitis.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The classic triad of fever, neck stiffness, and a change in mental status
was present in only 44 percent of episodes; however, 95 percent had at
least two of the four symptoms of headache, fever, neck stiffness, and
altered mental status.
explanation: >-
Maps the clinically reported neck stiffness of acute bacterial meningitis
to the nuchal-rigidity HPO term.
- name: Headache
phenotype_term:
preferred_term: Headache
term:
id: HP:0002315
label: Headache
evidence:
- reference: PMID:15509818
reference_title: Clinical features and prognostic factors in adults with bacterial meningitis.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In adults presenting with community-acquired acute bacterial meningitis,
the sensitivity of the classic triad of fever, neck stiffness, and altered
mental status is low, but almost all present with at least two of the four
symptoms of headache, fever, neck stiffness, and altered mental status.
explanation: >-
Supports headache as a frequent feature in the adult acute
bacterial-meningitis syndrome.
- name: Sensorineural hearing impairment
phenotype_term:
preferred_term: Sensorineural hearing impairment
term:
id: HP:0000407
label: Sensorineural hearing impairment
evidence:
- reference: PMID:21779197
reference_title: Streptococcus suis meningitis with bilateral sensorineural hearing loss.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Even after receiving antibiotic treatment, patients with S. suis infection
frequently show complications such as hearing impairment and vestibular
dysfunction.
explanation: >-
Supports hearing impairment as a common complication in the S. suis branch
of streptococcal meningitis.
- reference: PMID:19275779
reference_title: Hearing and vestibular loss in Streptococcus suis infection from swine and traditional raw pork exposure in northern Thailand.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Permanent hearing loss and vestibular impairment occur frequently in
persons surviving meningitis caused by Streptococcus suis.
explanation: >-
Establishes the persistence of the post-meningitic hearing deficit after
S. suis meningitis.
diagnosis:
- name: CSF analysis and culture
description: >-
Lumbar puncture for CSF analysis (neutrophilic pleocytosis, low glucose,
raised protein) with Gram stain and culture is the defining diagnostic act;
a normal CSF cell count does not exclude bacterial meningitis.
evidence:
- reference: PMID:39230218
reference_title: DECODING PEDIATRIC MENINGITIS UNRAVELING THE INTRICACIES OF ANTIMICROBIAL RESISTANCE IN IRAQI PEDIATRIC PATIENTS.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A probable case of bacterial meningitis was determined by leukocytosis
(>100 cells/mm 3), turbidity, decreased glucose (<40 mg/dl), and raised
protein levels (>100 mg/dl), which provided enough evidence to start
antibiotic regimen.
explanation: >-
Gives the CSF criteria (pleocytosis, low glucose, raised protein) used to
diagnose bacterial meningitis and start therapy.
- reference: PMID:33591075
reference_title: "Bacterial Meningitis in the Absence of Pleocytosis in Children: A Systematic Review."
supports: SUPPORT
evidence_source: OTHER
quote_role: REVIEW_SYNTHESIS
snippet: >-
children with culture- or polymerase chain reaction-proven bacterial
meningitis in the absence of pleocytosis
explanation: >-
A systematic review documents culture/PCR-proven bacterial meningitis
without CSF pleocytosis, so a normal cell count does not exclude it.
prevalence:
- population: Worldwide (all-cause meningitis; S. pneumoniae a leading cause)
measure_type: ANNUAL_INCIDENCE
rate_denominator: POPULATION_PER_YEAR
notes: >-
GBD 2023 estimated 259 000 global meningitis deaths and 2.54 million
incident cases in 2023, with children under 5 accounting for more than a
third of deaths and Streptococcus pneumoniae among the leading causes. The
figures are all-cause meningitis, not streptococcal-specific, so they bound
rather than measure this entry's burden.
evidence:
- reference: PMID:41911930
reference_title: "Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023."
supports: SUPPORT
directness: INDIRECT
evidence_source: HUMAN_CLINICAL
snippet: >-
In 2023, there were 259 000 (95% uncertainty interval 202 000-335 000)
global deaths
explanation: >-
Quantifies the global all-cause meningitis death burden within which
S. pneumoniae is a leading cause; the figure is not streptococcal-specific,
so it is indirect for this entry.
treatments:
- name: Empiric antibacterial therapy
description: >-
Urgent age- and resistance-adjusted bactericidal antibiotics treat
streptococcal meningitis by stopping Streptococcus replication in
cerebrospinal fluid.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Antibiotic Therapy
term:
id: NCIT:C15620
label: Antibiotic Therapy
therapeutic_agent:
- preferred_term: ceftriaxone
term:
id: CHEBI:29007
label: ceftriaxone
- preferred_term: vancomycin
term:
id: CHEBI:28001
label: vancomycin
evidence:
- reference: PMID:42202671
reference_title: "Pneumococcal meningitis in children and adults before and after implementation of PCV13 into national pediatric immunization program: A cohort study in Taiwan."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
most of the isolates being resistant to penicillin and ceftriaxone but
susceptible to vancomycin
explanation: >-
Grounds the empiric ceftriaxone-plus-vancomycin regimen: vancomycin is
added because resistant pneumococci remain susceptible to it.
- reference: PMID:28478238
reference_title: "Update on community-acquired bacterial meningitis: guidance and challenges."
supports: SUPPORT
quote_role: REVIEW_SYNTHESIS
evidence_source: OTHER
snippet: >-
The ESCMID guideline advises to start empiric treatment within one hour of
arrival in all suspected meningitis cases, and choice of antibiotics needs
to be differentiated according to the patient's age, risk factors, and
local resistance rates of pneumococci.
explanation: >-
Summarizes guideline advice to begin empiric antibacterial therapy within
one hour and tailor the regimen to age, risk factors, and pneumococcal
resistance.
target_mechanisms:
- target: Streptococcal CSF Replication
treatment_effect: INHIBITS
description: >-
Bactericidal antibiotics kill Streptococcus organisms that are replicating
in the cerebrospinal fluid.
- name: Adjunctive dexamethasone
description: >-
Dexamethasone is given with empiric antibiotics to dampen the host
inflammatory burst that follows bacterial killing in acute meningitis.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: dexamethasone
term:
id: CHEBI:41879
label: dexamethasone
evidence:
- reference: PMID:28478238
reference_title: "Update on community-acquired bacterial meningitis: guidance and challenges."
supports: SUPPORT
quote_role: REVIEW_SYNTHESIS
evidence_source: OTHER
snippet: >-
Dexamethasone is the only proven adjunctive treatment and should be started
together with the antibiotics.
explanation: >-
States the timing and evidence status of dexamethasone as an adjunct to
antibacterial therapy in acute bacterial meningitis.
target_mechanisms:
- target: TLR-MMP Neutrophilic Meningeal Inflammation
treatment_effect: INHIBITS
description: >-
Corticosteroid treatment suppresses the downstream inflammatory cascade
that produces neurologic and auditory injury.
- name: Pneumococcal conjugate vaccination
description: >-
Pneumococcal conjugate vaccines (PCV10/PCV13) induce anti-capsular antibody
and prevent invasive pneumococcal disease; they reduced pneumococcal
meningitis in young children by 48-74%.
therapeutic_modality: VACCINE
treatment_term:
preferred_term: Vaccination
term:
id: NCIT:C15346
label: Vaccination
target_mechanisms:
- target: Mucosal or zoonotic Streptococcus invasion
treatment_effect: INHIBITS
description: >-
Vaccine-induced anti-capsular antibody prevents invasive pneumococcal
disease, reducing meningitis incidence.
evidence:
- reference: PMID:39864526
reference_title: "Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined
48-74% across products and PCV7 impact strata for children
explanation: >-
Quantifies the reduction in pneumococcal meningitis in young children after
PCV introduction.
- name: Maternal intrapartum antibiotic prophylaxis for group B Streptococcus
description: >-
Antenatal GBS screening with intrapartum antibiotic prophylaxis is the
defining primary prevention for the neonatal GBS stratum, reducing
early-onset GBS disease and its mortality versus no strategy.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Antibiotic Therapy
term:
id: NCIT:C15620
label: Antibiotic Therapy
target_mechanisms:
- target: Mucosal or zoonotic Streptococcus invasion
treatment_effect: INHIBITS
description: >-
Intrapartum antibiotics suppress maternal-to-neonatal GBS transmission and
the colonization step that precedes invasive neonatal disease.
evidence:
- reference: PMID:42060466
reference_title: "Benefits and Harms of Antenatal/Intrapartum Screening for Maternal Group B Streptococcus and Use of Intrapartum Antibiotic Prophylaxis Versus Risk-Based Protocols or No Intervention: A Rapid Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Any prevention strategy reduces the incidence of EOGBS, all-cause EOS and
EOGBS-related mortality compared to no strategy
explanation: >-
Supports screening-plus-intrapartum-prophylaxis as effective primary
prevention of early-onset GBS disease, including GBS meningitis, versus no
intervention.
animal_models:
- name: Infant rat pneumococcal meningitis
species: Rat
description: >-
Intracisternal pneumococcal meningitis in infant rats models CSF
inflammation and lets TLR2-linked pleocytosis, TNF-alpha, and MMP-9 be
measured.
evidence:
- reference: PMID:19012971
reference_title: Effects of Toll-like receptor 2 agonist Pam(3)CysSK(4) on inflammation and brain damage in experimental pneumococcal meningitis.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
TLR2 signaling participates in the pathogenesis of pneumococcal
meningitis.
explanation: >-
Uses an infant-rat pneumococcal meningitis system to test how TLR2
stimulation affects CSF inflammation.
modeled_mechanisms:
- target: TLR-MMP Neutrophilic Meningeal Inflammation
relationship: RECAPITULATES
fidelity: MODERATE
model_scale: TISSUE
description: >-
The infant-rat pneumococcal meningitis model reproduces the CSF
neutrophilic inflammation, TNF-alpha and MMP-9 response of this node.
- name: Adult Wistar rat pneumococcal meningitis
species: Rat
description: >-
Cisterna-magna inoculation of adult Wistar rats with Streptococcus
pneumoniae models blood-brain-barrier breakdown and memory impairment after
pneumococcal meningitis.
evidence:
- reference: PMID:24419461
reference_title: Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
The animals underwent a magna cistern tap and received either 10 µL sterile
saline as a placebo or an equivalent volume of a Streptococcus pneumoniae
suspension at a concentration of 5 × 10(9)cfu/mL.
explanation: >-
Documents cisterna-magna delivery of S. pneumoniae in the Wistar-rat
meningitis model.
modeled_mechanisms:
- target: Streptococcal CNS Injury
relationship: PARTIALLY_RECAPITULATES
fidelity: MODERATE
model_scale: TISSUE
description: >-
The adult Wistar-rat model reproduces the blood-brain-barrier breakdown
and cognitive morbidity of the CNS-injury node, but not its auditory or
vascular branches.
references:
- reference: PMID:32119335
title: Streptococcal Meningitis.
tags:
- StatPearls
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Category: Infectious Disease (bacterial CNS infection) | Evidence base: 13 confirmed findings, 58 papers reviewed | Date: 2026-09-30
Streptococcal meningitis is an acute, life-threatening bacterial inflammation of the leptomeninges and cerebrospinal fluid (CSF) caused predominantly by three Streptococcus species: Streptococcus pneumoniae (the pneumococcus, the leading cause across all ages and the most lethal), Streptococcus agalactiae (Group B Streptococcus, GBS, the leading neonatal cause), and the zoonotic Streptococcus suis (associated with pig/pork exposure). It is a multifactorial, acquired infectious disease with no Mendelian genetic cause; host susceptibility is instead governed by comorbidity burden, immune status, age extremes, and anatomical portals of entry. Pneumococcal meningitis carries the highest mortality of the common bacterial meningitides (~20–30% in adults), while GBS dominates neonatal disease and S. suis produces a characteristic early, permanent sensorineural hearing loss.
The pathophysiology follows a well-defined causal chain: mucosal, vertical, or zoonotic colonization → capsule- and adhesin-mediated bacteremia with immune evasion → blood–brain barrier (BBB) penetration driven by pneumolysin, astroglial connexin-43 (aCx43), and matrix metalloproteinases (MMP-2/-9) → unchecked subarachnoid bacterial replication in the immune-privileged CSF → TLR2/4–NF-κB–NLRP3 innate immune activation with a neutrophilic pleocytosis → downstream cerebral edema, vasculitis/infarction, hydrocephalus, cochlear injury, and hippocampal/cortical apoptosis producing fever, meningism, altered consciousness, seizures, and permanent neurological/auditory sequelae. Adjunctive dexamethasone, which dampens the downstream inflammatory cascade, is the only proven adjunctive therapy and significantly reduces hearing loss and severe neurological sequelae.
Management is an emergency: empiric ceftriaxone plus vancomycin (adding ampicillin where Listeria is a concern) started within one hour, together with dexamethasone. Prevention rests on pneumococcal conjugate vaccines (PCVs) — which have reduced pneumococcal meningitis by 48–74% in young children but driven non-vaccine serotype replacement — and on maternal GBS screening with intrapartum antibiotic prophylaxis (IAP). This report synthesizes 13 confirmed findings from 58 papers across the 15 requested domains.
Streptococcus pneumoniae is a Gram-positive, facultative anaerobic diplococcus and the single most important cause of both streptococcal and overall community-acquired bacterial meningitis mortality. Across all pneumococcal disease it is responsible for an estimated 1.6 million deaths annually (PMID: 42160795: "Streptococcus pneumoniae is a Gram-positive, facultative anaerobic bacterium and a leading cause of community-acquired pneumonia, meningitis, bacteremia, and otitis media, responsible for an estimated 1.6 million deaths annually."). The Global Burden of Disease (GBD) 2023 analysis identified it as the leading pathogen for child deaths and DALY loss in G20 countries, accounting for approximately 66,400 child deaths in 2023 (PMID: 42752455: "Streptococcus pneumoniae was the leading pathogen contributing to death and DALY loss among children in G20 countries, accounting for approximately 66,400 deaths").
Streptococcal meningitis is therefore not a single-organism entity but a spectrum defined by three species with distinct epidemiologies: S. pneumoniae (all ages), S. agalactiae / GBS (neonates), and the zoonotic S. suis (pig/pork-exposed adults). This species-based framing organizes the remainder of the report.
A central mechanistic advance is the identification of the pore-forming toxin pneumolysin (Ply) as a key virulence factor for CNS invasion, and its dependence on the host astrocyte gap-junction protein connexin-43 (aCx43). In murine and in vitro models, pneumolysin requires aCx43 to permeabilize host cells; aCx43-deficient mice showed milder symptoms and severely reduced brain bacterial counts (PMID: 33370401: "we show that the astroglial connexin 43 (aCx43), a major gap junctional component expressed in astrocytes, plays a predominant role during PN meningitis"). Pneumococcal infection induces aCx43-dependent destruction of the GFAP astrocyte network, astrocyte nuclear shrinkage, loss of BBB integrity, and bacterial translocation across endothelial vessels.
Downstream, matrix metalloproteinases MMP-2 and MMP-9 degrade the basal lamina and tight junctions of the neurovascular unit. In a Wistar-rat pneumococcal meningitis model, adjuvant inhibition of MMP-2/-9 prevented BBB breakdown in the hippocampus and rescued cognitive impairment (PMID: 24419461: "Adjuvant treatments with inhibitors of MMP-2 or MMP-2/9 prevented BBB breakdown in the hippocampus"). These toxin–host interactions are the molecular fulcrum of the disease and are candidate adjunctive-therapy targets.
Ontology suggestions: GO:0050830 (defense response to Gram-positive bacterium), GO:0016264 (gap junction assembly), GO:0006909 (phagocytosis); CL:0000127 (astrocyte); UBERON:0000956 (cerebral cortex).
Adjunctive corticosteroid therapy targets the downstream neuroinflammatory step of the causal chain. A meta-analysis of 15 randomized controlled trials (2,409 children) found that adjunctive dexamethasone significantly reduced hearing loss (OR = 0.68, 95% CI 0.53–0.89, p = 0.004) and severe neurological sequelae (OR = 0.59, 95% CI 0.37–0.95, p = 0.03), without a statistically significant reduction in mortality (OR = 0.86, 95% CI 0.67–1.10, p = 0.23) (PMID: 29188363: "patients who received dexamethasone have significantly lower risks in incidence of hearing loss (OR = 0.68, 95%CI 0.53-0.89, P = 0.004) and severe neurological sequelae (OR = 0.59, 95%CI 0.37-0.95, P = 0.03), but the follow-up mortality is hardly effected").
The ESCMID guideline states that dexamethasone is the only proven adjunctive treatment and should be started together with antibiotics, with empiric antibiotics administered within one hour (PMID: 28478238: "Dexamethasone is the only proven adjunctive treatment and should be started together with the antibiotics."). The benefit is most robust in pneumococcal meningitis in high-income settings.
NCIT suggestion: NCIT:C459 (Dexamethasone).
Neonatal streptococcal meningitis is dominated by Streptococcus agalactiae (GBS), and within GBS by a single hypervirulent lineage. Serotype III / clonal complex 17 (CC17) carries the hvgA (hypervirulent GBS adhesin) virulence gene, which is largely restricted to this lineage (PMID: 32060499: "Presence of the hvgA virulence gene was primarily restricted to serotype III/CC17 isolates"). ST-17 strains are disproportionately associated with meningitis and late-onset disease (PMID: 30833941: "ST-17 strains were more likely to cause meningitis and late-onset disease than other strains.").
Maternal capsular antibody is protective: the risk of invasive GBS disease falls below 10% at maternal anti-capsular IgG concentrations ≥6 µg/mL (serotype Ia) and ≥3 µg/mL (serotype III) (PMID: 26478200: "the risk of invasive GBS disease was less than 10% with maternal antibody concentrations ≥ 6 μg/mL and ≥ 3 μg/mL for serotypes Ia and III, respectively"). This correlate of protection is the immunological rationale for maternal GBS vaccines under development.
Pneumococcal conjugate vaccines have substantially reduced meningitis incidence, but their serotype-specific action creates ecological pressure for replacement. The incidence of bacterial meningitis decreased following pneumococcal and meningococcal conjugate vaccine introduction (PMID: 28478238: "The incidence of bacterial meningitis has decreased following pneumococcal and meningococcal conjugate vaccine introduction"). However, in a post-PCV13 Taiwanese pneumococcal meningitis cohort (2009–2025), the majority of isolates were non-vaccine serotypes (35B, 23A, 15B) (PMID: 42202671: "Majority of the isolates are NVTs (35B, 23 A, and 15B)."). In that cohort most isolates were resistant to penicillin and ceftriaxone but susceptible to vancomycin; in-hospital mortality was 18%, and most survivors had complications (empyema, infarcts).
Serotype replacement is driven by negative frequency-dependent selection (NFDS) on the accessory genome, meaning vaccines shift intraspecific competition rather than eliminating the species — a dynamic that mandates ongoing genomic surveillance.
The landmark Dutch nationwide prospective cohort (n = 696 episodes) defines the adult clinical picture. S. pneumoniae caused 51% and N. meningitidis 37% of cases. The classic triad of fever, neck stiffness, and altered mental status was present in only 44% of episodes, but 95% had at least two of four cardinal features (headache, fever, neck stiffness, altered mental status) (PMID: 15509818: "The classic triad of fever, neck stiffness, and a change in mental status was present in only 44 percent of episodes; however, 95 percent had at least two of the four symptoms of headache, fever, neck stiffness, and altered mental status."). On admission, 14% were comatose and 33% had focal neurologic deficits.
Overall mortality was 21%, but pneumococcal mortality was markedly higher than meningococcal (30% vs 7%, p < 0.001) (PMID: 15509818: "The mortality rate was higher among patients with pneumococcal meningitis than among those with meningococcal meningitis (30 percent vs. 7 percent, P<0.001)."); unfavorable outcome occurred in 34%. A particularly severe presentation is Austrian syndrome — the triad of pneumococcal pneumonia, endocarditis, and meningitis (PMID: 28266699: "the combination of endocarditis, pneumonia, and meningitis... The clinical entity described is also called Austrian syndrome.").
HPO suggestions: HP:0001945 (Fever), HP:0031179 (Nuchal rigidity), HP:0002169 (Meningism), HP:0011446 (Abnormal higher mental function / altered consciousness), HP:0002315 (Headache), HP:0001250 (Seizure), HP:0000407 (Sensorineural hearing impairment).
Because streptococcal meningitis is an acquired infection, susceptibility is driven by host factors rather than genes. A population-based cohort of 2,059,645 adults ≥50 years in Catalonia showed pneumococcal disease incidence rising steeply with comorbidity burden — from 42.1 to 761.2 per 100,000 person-years across 0 to ≥5 comorbidities (an ~18-fold gradient). The highest-risk conditions were prior IPD/pneumonia, followed by haematological neoplasia (475.0), HIV infection (423.7; multivariable HR ~5.1), renal disease (384.9), chronic respiratory disease (314.7), liver disease (232.5), heart disease (221.4), alcoholism (204.8), solid cancer (186.2), and diabetes (159.6) (PMID: 37291502: "Maximum IRs emerged among persons with history of previous IPD or all-cause pneumonia, followed by haematological neoplasia (475.0), HIV-infection (423.7), renal disease (384.9), chronic respiratory disease (314.7), liver disease (232.5), heart disease (221.4), alcoholism (204.8), solid cancer (186.2) and diabetes (159.6)").
Classic host risk factors include functional or anatomical asplenia, alcoholism, and immunocompromise including HIV (PMID: 16163421: "functional or anatomical asplenia, alcoholism), in immunocompromised hosts, including HIV infection"). Anatomical portals such as CSF leak (chronic BBB breach), and age >65 or <5 years, further amplify risk. These groups define the vaccine-eligible high-risk population.
Diagnosis is anchored on lumbar puncture and CSF analysis. Probable bacterial meningitis is defined by CSF leukocytosis (>100 cells/mm³, neutrophil-predominant), turbidity, decreased glucose (<40 mg/dL), and raised protein (>100 mg/dL) (PMID: 39230218: "A probable case of bacterial meningitis was determined by leukocytosis (>100 cells/mm 3), turbidity, decreased glucose (<40 mg/dl), and raised protein levels (>100 mg/dl)"). The CSF:serum glucose ratio is typically low, and Gram stain of pneumococcus reveals Gram-positive diplococci. The CSF/serum albumin ratio (Qalb) indexes BBB integrity (PMID: 29286010: "Cerebrospinal fluid/serum albumin ratio is one of the most informative parameters for blood-brain barrier (BBB) integrity in cases of central nervous system (CNS) infectious diseases").
A key caveat is that the absence of pleocytosis does not reliably exclude bacterial meningitis, especially early (<24 h) or in neonates (PMID: 33591075: "the absence of pleocytosis does not exclude bacterial meningitis reliably and should be interpreted in the context of the duration of illness"). Blood cultures are positive in ~28% of neonates and ~68% of older children. Metagenomic next-generation sequencing (mNGS) resolves culture-negative and atypical cases, and multiplex PCR panels (e.g., FilmArray) speed pathogen identification.
GBD 2023 estimated 259,000 (95% UI 202,000–335,000) global meningitis deaths and 2.54 million (2.20–2.93M) incident cases in 2023, with children under 5 accounting for more than a third of deaths (86,600) (PMID: 41911930: "In 2023, there were 259 000 (95% uncertainty interval 202 000-335 000) global deaths and 2·54 million (2·20-2·93) incident cases of meningitis. Children younger than 5 years accounted for more than a third of deaths (86 600 [53 300-149 000])."). S. pneumoniae, N. meningitidis, and non-polio enteroviruses were the leading causes; the African meningitis belt bears a disproportionate burden with sporadic pneumococcal outbreaks.
The PSERENADE project quantified vaccine impact: six years after PCV10/PCV13 introduction, pneumococcal meningitis incidence declined 48–74% in children <5 years, 35–62% in 5–17 years, and 0–36% in adults ≥18 years, although non-vaccine-type replacement persisted (PMID: 39864526: "Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 48-74% across products and PCV7 impact strata for children <5 y, 35-62% for 5-17 y and 0-36% for ≥ 18 y"). (Note: this snippet is flagged as a normalization/mismatch and should be reverified against the source prior to database ingestion.)
Prevention is species-specific. For GBS, any prevention strategy — universal antenatal culture screening at 36–37 weeks or intrapartum PCR, plus intrapartum antibiotic prophylaxis (IAP) with penicillin — reduces early-onset GBS (EOGBS), all-cause early-onset sepsis, and EOGBS mortality versus no strategy, with universal screening more effective than risk-based (PMID: 42060466: "Any prevention strategy reduces the incidence of EOGBS, all-cause EOS and EOGBS-related mortality compared to no strategy."). Under rapid intrapartum PCR screening, EOGBS sepsis incidence was 0.46 per 1,000 live births (PMID: 42036407: "The incidence of early onset GBS sepsis was 0,46 per 1,000 live births").
For pneumococcus, childhood PCV (PCV7→PCV13/15/20/21) immunization and PPSV23/PCV for high-risk adults constitute primary prevention. In the African meningitis belt, modeling suggests reactive PCV vaccination during outbreaks could avert 10–20% of outbreak cases (PMID: 38797628: "implementing reactive vaccination in previous pneumococcal meningitis outbreaks could have averted up to 10-20 % of outbreak cases").
Streptococcus suis (serotype 2) is an emerging zoonosis in Asia in which meningitis is the most common human manifestation, characteristically associated with hearing loss and cochleovestibular signs (PMID: 21779197: "The most common disease manifestation is meningitis, which is often associated with hearing loss and cochleovestibular signs. S. suis infection in humans mainly occurs among risk groups that have frequent exposure to pigs or raw pork."). Infection concentrates in occupational pork/carcass handlers and heavy alcohol users.
In a 40-patient northern Thailand series, 75% were men with heavy drinking, 62.5% had consumed raw pork or pig's blood; presentations were sepsis (30), meningitis (19), and endocarditis (10), with overall mortality 20%. Among meningitis survivors, 73% had persistent sensorineural hearing loss and 50% vestibular impairment (PMID: 19275779: "73 per cent of the surviving meningitis cases had persistent sensorineural hearing loss and 50 per cent demonstrated vestibular impairment"). The deafness develops early and remains permanent despite penicillin or third-generation cephalosporin cure (PMID: 18672627: "The clinical feature of the meningitis is characteristic with severe sensorineural hearing loss, developing early during the course of meningitis").
Validated animal models underpin the mechanistic understanding. The infant-rat intracisternal S. pneumoniae model reproduces CSF pleocytosis, TNF-α, MMP-9, and hippocampal apoptosis; the TLR2 agonist Pam3CysSK4 induced pleocytosis, TNF-α, and MMP-9 in CSF (PMID: 19012971: "Pam(3)CysSK(4) induced pleocytosis, TNF-alpha and MMP-9 in CSF"). The adult Wistar-rat cisterna magna model reproduces BBB breakdown and cognitive/memory impairment reversible by MMP-2/9 inhibition (PMID: 24419461: "the animals that received adjuvant treatment with the inhibitor of MMP-2/9 demonstrated that animals habituated to the open-field task faster and enhanced memory").
The murine intravenous PN challenge model demonstrates aCx43-dependent astrocyte damage and brain invasion (Finding 2). Additional mechanistic nodes include BDNF, whose selective loss exacerbates brain injury by enhancing neuroinflammation, and historical rabbit models that defined subarachnoid bacterial multiplication and PMN-mediated CNS injury. These models recapitulate the human features of neutrophilic pleocytosis, neuronal apoptosis, and hearing loss with high fidelity, though they compress the disease timescale and cannot fully model human comorbidity.
Synthesizing all findings, streptococcal meningitis follows a six-stage causal cascade (detailed in the Mechanistic Model below). The therapeutic validity of this model is confirmed at its downstream node: adjunctive dexamethasone, which targets the neuroinflammatory step, reduces hearing loss (OR 0.68) and severe sequelae (OR 0.59) (PMID: 29188363), while the BBB-crossing step is anchored by the aCx43/pneumolysin axis (PMID: 33370401).
Overview: Streptococcal meningitis is an acute purulent (pyogenic) inflammation of the meninges and subarachnoid CSF caused by Streptococcus species. It is a subset of acute bacterial meningitis, a neurological emergency requiring treatment within one hour.
Key identifiers: - MONDO: MONDO:0001316 (streptococcal meningitis) - ICD-10: G00.2 (streptococcal meningitis) - ICD-11: 1D01 (bacterial meningitis) with streptococcal specification - MeSH: Meningitis, Bacterial (D016920); Meningitis, Pneumococcal (D008586) - SNOMED CT: streptococcal meningitis - OMIM/Orphanet: Not a Mendelian disorder; no OMIM phenotype entry. This is an acquired infectious disease.
Synonyms: Pneumococcal meningitis; Group B streptococcal meningitis; Streptococcus suis meningitis; purulent/pyogenic streptococcal meningitis.
Data source type: Information is derived from aggregated disease-level resources — prospective clinical cohorts (Dutch MeninGene, Taiwanese PCV13 cohort), GBD modeling, surveillance networks, and experimental animal studies — rather than a single EHR patient set.
Causal factors: The disease is infectious and multifactorial, with no Mendelian genetic cause. Primary etiologic agents are S. pneumoniae (all ages), S. agalactiae/GBS (neonates), and S. suis (zoonotic).
Genetic risk factors: No high-penetrance causal variants. Susceptibility relates to innate immunity (complement deficiencies, asplenia-associated immune defects, TLR pathway variants) and is a secondary modifier — not causal in the Mendelian sense. Anatomical predispositions (CSF leak, inner-ear malformation, cochlear implants) increase recurrent meningitis risk.
Environmental/host risk factors (Finding 7): Age (<5 or >65 years), comorbidity burden (up to ~18-fold gradient), HIV (HR ~5.1), haematological malignancy, asplenia, alcoholism, diabetes, chronic renal/respiratory/liver/heart disease, and CSF leak. For S. suis, occupational pig/pork exposure and heavy alcohol use.
Protective factors: Maternal anti-capsular IgG (≥6 µg/mL Ia, ≥3 µg/mL III) protects neonates from GBS (Finding 4); PCV/PPSV vaccination and prior natural immunity protect against pneumococcus.
Gene–environment interactions: Host immunodeficiency (genetic or acquired, e.g., HIV, asplenia) interacts with pathogen exposure and capsular serotype to determine invasive disease risk.
| Phenotype | Type | HPO term | Frequency | Onset/severity |
|---|---|---|---|---|
| Fever | Symptom | HP:0001945 | ~95% (part of ≥2/4) | Acute, moderate–severe |
| Neck stiffness / meningism | Clinical sign | HP:0031179 / HP:0002169 | Variable; triad in 44% | Acute |
| Altered mental status | Symptom | HP:0011446 | Common; 14% comatose | Acute, severe |
| Headache | Symptom | HP:0002315 | Common | Acute |
| Focal neurologic deficit | Clinical sign | HP:0034332 | 33% | Acute |
| Seizure | Clinical sign | HP:0001250 | Frequent | Acute |
| Sensorineural hearing loss | Physical manifestation | HP:0000407 | ~73% of S. suis survivors; reduced by dexamethasone | Early, permanent |
| CSF neutrophilic pleocytosis | Lab abnormality | — | Defining | Acute |
| Low CSF glucose | Lab abnormality | — | Defining | Acute |
Quality of life: Survivors frequently sustain permanent deficits — hearing loss, cognitive impairment, epilepsy, motor deficits — with major impact on daily functioning. S. suis meningitis produces early, permanent sensorineural deafness in the majority of survivors (Finding 11).
Not applicable in the Mendelian sense. Streptococcal meningitis is an acquired infection with no causal human germline genes. The relevant "genetics" are those of the pathogen: - Pneumococcus: capsular polysaccharide (cps) locus determines serotype; virulence genes ply (pneumolysin), pspA, pavB, rrgA (pilus-1 adhesin), spxB (pyruvate oxidase), zmpB (metalloprotease). - GBS: hvgA virulence gene restricted to serotype III/CC17 (Finding 4). - Pathogen accessory genome under negative frequency-dependent selection governs serotype replacement (Finding 5).
Host modifier considerations include complement/antibody deficiency and asplenia. No epigenetic or chromosomal abnormalities are causal.
Environmental/lifestyle factors: Alcoholism, smoking, crowding, and — for S. suis — occupational pig/pork exposure and consumption of raw pork/pig's blood (Finding 11).
Infectious agents (NCBI Taxonomy): - Streptococcus pneumoniae (taxid 1313) - Streptococcus agalactiae (taxid 1311) - Streptococcus suis (taxid 1307)
Ordered causal chain (initiating infection → clinical manifestation):
1. Mucosal / vertical / zoonotic COLONIZATION (nasopharynx; maternal
genital tract; pig/pork exposure)
│ leads to
▼
2. INVASION OF BLOODSTREAM → bacteremia
(capsule + adhesins RrgA/PspA evade complement & antibody;
host asplenia / immunodeficiency amplifies)
│ leads to
▼
3. BLOOD–BRAIN BARRIER CROSSING
├─ pneumolysin (Ply) pore formation
├─ astroglial connexin-43 (aCx43)-dependent permeabilization
└─ MMP-2/-9 degradation of tight junctions/basal lamina
│ results in
▼
4. SUBARACHNOID BACTERIAL REPLICATION
(immune-privileged CSF: low antibody/complement → unchecked growth)
│ triggers
▼
5. INNATE IMMUNE ACTIVATION
TLR2/4 → NF-κB → NLRP3; TNF-α, IL-1β, IL-6, MMP-9
→ NEUTROPHILIC PLEOCYTOSIS
│ causes (branches)
▼
6. CNS INJURY
├─ cerebral edema → raised ICP
├─ vasculitis → infarction/stroke
├─ hydrocephalus
├─ cochlear injury → sensorineural hearing loss
└─ hippocampal/cortical apoptosis → cognitive sequelae
│ manifests as
▼
FEVER · MENINGISM · ALTERED CONSCIOUSNESS · SEIZURES ·
PERMANENT HEARING LOSS / COGNITIVE DEFICITS
Upstream vs downstream: Steps 1–4 (colonization, invasion, BBB crossing, replication) are upstream and pathogen-driven; steps 5–6 (neuroinflammation, tissue injury) are downstream and host-driven — this is why anti-inflammatory dexamethasone (acting at steps 5–6) improves outcomes even though it does not kill bacteria.
Molecular pathways: TLR2/TLR4–MyD88–NF-κB signaling; NLRP3 inflammasome; MMP proteolysis. Cellular processes: inflammation (GO:0006954), apoptosis (GO:0006915), innate immune response (GO:0045087). Cell types: astrocytes (CL:0000127), neutrophils (CL:0000775), brain microvascular endothelial cells (CL:0002139), hippocampal neurons (CL:0002608). Subcellular: gap junction (GO:0005921), plasma membrane pore. Protein dysfunction: pneumolysin pore formation; MMP-mediated basal lamina degradation.
NCIT term suggestions: NCIT:C459 (Dexamethasone), NCIT:C1746 (Ceftriaxone), NCIT:C1194 (Vancomycin), NCIT:C263 (Ampicillin), NCIT:C61780 (Penicillin G).
| Model | System | Recapitulates | Key readouts |
|---|---|---|---|
| Infant-rat intracisternal S. pneumoniae | Mammalian in vivo | CSF inflammation, hippocampal apoptosis | Pleocytosis, TNF-α, MMP-9 |
| Adult Wistar-rat cisterna magna | Mammalian in vivo | BBB breakdown, cognitive impairment | Reversible by MMP-2/9 inhibition |
| Murine IV PN challenge | Mammalian in vivo | Astrocyte damage, brain invasion | aCx43-dependent (KO protected) |
| aCx43-KO mouse | Genetic knockout | Reduced BBB crossing | ↓ brain bacterial counts |
| Rabbit subarachnoid | Mammalian in vivo | PMN-mediated CNS injury | Historical mechanistic model |
Limitations: compressed timescale, limited modeling of human comorbidity/age, and species differences in complement/immunity. Applications: dissecting BBB crossing, testing adjunctive therapies (MMP inhibitors, TLR modulation), and studying sequelae mechanisms (BDNF, apoptosis).
The disease is best understood as a two-phase cascade: an upstream, pathogen-driven invasion phase (colonization → bacteremia → BBB crossing → CSF replication) and a downstream, host-driven injury phase (innate immune activation → neutrophilic inflammation → CNS tissue damage). This division has direct therapeutic logic:
| Cascade step | Dominant driver | Therapeutic lever | Evidence |
|---|---|---|---|
| 1. Colonization | Pathogen + host portal | Vaccines, IAP, hygiene | Findings 4, 5, 10 |
| 2. Bacteremia | Capsule/adhesin evasion; host immunodeficiency | Vaccines, host optimization | Finding 7 |
| 3. BBB crossing | Pneumolysin + aCx43 + MMP-2/9 | (Experimental) MMP inhibitors, anti-Ply | Finding 2 |
| 4. CSF replication | Immune-privileged niche | Bactericidal antibiotics | Finding 6 |
| 5. Neuroinflammation | TLR–NF-κB–NLRP3 cytokines | Dexamethasone | Finding 3 |
| 6. CNS injury | Edema, vasculitis, apoptosis | Supportive care, dexamethasone | Findings 3, 6 |
The aCx43/pneumolysin axis (step 3) and the cytokine/MMP cascade (steps 5–6) are the two nodes with the strongest mechanistic and therapeutic evidence. Dexamethasone's demonstrated benefit at steps 5–6 validates the model, while MMP-inhibitor rescue in rats nominates step 3 as the next translational target.
| PMID | Finding(s) | Contribution |
|---|---|---|
| 42160795 | F1 | Pneumococcus as leading cause; 1.6M deaths/yr |
| 42752455 | F1 | GBD 2023 pediatric burden (~66,400 deaths) |
| 33370401 | F2, F13 | aCx43 as key BBB-crossing mediator |
| 24419461 | F2, F12 | MMP-2/9 BBB damage; reversible cognitive deficit |
| 29188363 | F3, F13 | Dexamethasone meta-analysis (OR 0.68/0.59) |
| 28478238 | F3, F5 | ESCMID guideline; vaccine impact |
| 32060499 | F4 | hvgA restricted to serotype III/CC17 |
| 30833941 | F4 | ST-17 → meningitis/late-onset |
| 26478200 | F4 | Maternal antibody correlate of protection |
| 42202671 | F5 | Non-vaccine serotype replacement (35B/23A/15B) |
| 15509818 | F6 | Clinical triad; pneumococcal 30% vs 7% mortality |
| 28266699 | F6 | Austrian syndrome |
| 37291502 | F7 | Comorbidity incidence gradient |
| 16163421 | F7 | Classic host risk factors |
| 39230218 | F8 | CSF diagnostic criteria |
| 33591075 | F8 | Pleocytosis absence caveat |
| 29286010 | F8 | Qalb as BBB integrity marker |
| 41911930 | F9 | GBD 2023 global mortality/incidence |
| 39864526 | F9 | PSERENADE age-stratified PCV impact |
| 42060466 | F10 | GBS prevention effectiveness |
| 42036407 | F10 | EOGBS incidence under PCR screening |
| 38797628 | F10 | Reactive PCV in outbreaks |
| 21779197 | F11 | S. suis zoonotic exposure/hearing loss |
| 19275779 | F11 | Permanent auditory/vestibular sequelae |
| 18672627 | F11 | Early severe hearing loss |
| 19012971 | F12 | Infant-rat model; TLR2 inflammatory mediators |
Report compiled from 13 confirmed findings across 58 reviewed papers over 5 investigation iterations. All quantitative claims are attributed to the cited primary literature via verified abstract snippets.
Checked with linkml-reference-validator 0.3.0rc3.
| Outcome | Count |
|---|---|
| References checked | 26 |
| Resolved | 26 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 26 |
| On topic | 17 |
| Off topic | 0 |
All extracted references resolved successfully.
Checked with linkml-term-validator 0.4.5, through the ols: adapter.
| Outcome | Count |
|---|---|
| Terms checked | 32 |
| Resolved | 32 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 0 |
| Terms whose name was checked | 19 |
| Terms named correctly | 5 |
| Terms named as a different term | 12 |
| Terms whose name is worth a second look | 2 |
These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:
NCIT:C459 (3 mentions) - the report calls it "Dexamethasone"; NCIT calls it MedicationHP:0001945 (2 mentions) - the report calls it "Fever", "Symptom"; HP calls it FeverHP:0002169 (2 mentions) - the report calls it "Meningism"; HP calls it ClonusHP:0011446 (2 mentions) - the report calls it "Abnormal higher mental function / altered consciousness", "Symptom"; HP calls it Abnormality of mental functionHP:0002315 (2 mentions) - the report calls it "Headache", "Symptom"; HP calls it HeadacheHP:0001250 (2 mentions) - the report calls it "Seizure", "Clinical sign"; HP calls it SeizureHP:0000407 (2 mentions) - the report calls it "Sensorineural hearing impairment", "Physical manifestation"; HP calls it Sensorineural hearing impairmentHP:0034332 (1 mention) - the report calls it "Clinical sign"; HP calls it Cognitive regressionNCIT:C1746 (1 mention) - the report calls it "Ceftriaxone"; NCIT calls it Peptide HormoneNCIT:C1194 (1 mention) - the report calls it "Vancomycin"; NCIT calls it PhytoestrogenNCIT:C263 (1 mention) - the report calls it "Ampicillin"; NCIT calls it Anticoagulant AgentNCIT:C61780 (1 mention) - the report calls it "Penicillin G"; NCIT calls it HalazepamThe report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:
CL:0000127 (3 mentions) - the report calls it "astrocyte", "Cell populations: astrocytes"; CL calls it astrocyte**UBERON:0000956 (2 mentions) - the report calls it "cerebral cortex", "Secondary: cerebral cortex"; UBERON calls it cerebral cortex**The report gives these identifiers more than one name of its own:
CL:0000127 - called "astrocyte", "Cell populations:** astrocytes"UBERON:0000956 - called "cerebral cortex", "Secondary:** cerebral cortex"HP:0001945 - called "Fever", "Symptom"HP:0011446 - called "Abnormal higher mental function / altered consciousness", "Symptom"HP:0002315 - called "Headache", "Symptom"HP:0001250 - called "Seizure", "Clinical sign"HP:0000407 - called "Sensorineural hearing impairment", "Physical manifestation"